CENTOGENE GmbH: CENTOGENE and Alnylam Pharmaceuticals Launch a New Clinical Program Aimed at Revolutionizing the Diagnosis of Hereditary Transthyretin-Related Amyloidosis (“ATTRv”)

Written by Petra Hegmann on 8th December 2020. Posted in Client News.